Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand

Core Viewpoint - Eli Lilly forecasts 2026 profit exceeding Wall Street estimates due to strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro, which are expected to counteract pricing pressures in the U.S. market [1] Group 1 - Eli Lilly anticipates robust demand for its blockbuster drugs, Zepbound and Mounjaro, contributing to profit growth [1] - The company expects to overcome pricing pressures in its largest market, the U.S., through the success of these drugs [1]